These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12632504)

  • 1. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract.
    Liang W; Wang H; Sun TM; Yao WQ; Chen LL; Jin Y; Li CL; Meng FJ
    World J Gastroenterol; 2003 Mar; 9(3):495-8. PubMed ID: 12632504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma.
    Ockert D; Schirrmacher V; Beck N; Stoelben E; Ahlert T; Flechtenmacher J; Hagmüller E; Buchcik R; Nagel M; Saeger HD
    Clin Cancer Res; 1996 Jan; 2(1):21-8. PubMed ID: 9816085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine.
    Lehner B; Schlag P; Liebrich W; Schirrmacher V
    Cancer Immunol Immunother; 1990; 32(3):173-8. PubMed ID: 2289211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial.
    Schlag P; Manasterski M; Gerneth T; Hohenberger P; Dueck M; Herfarth C; Liebrich W; Schirrmacher V
    Cancer Immunol Immunother; 1992; 35(5):325-30. PubMed ID: 1394336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.
    Batliwalla FM; Bateman BA; Serrano D; Murray D; Macphail S; Maino VC; Ansel JC; Gregersen PK; Armstrong CA
    Mol Med; 1998 Dec; 4(12):783-94. PubMed ID: 9990864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer.
    Ahlert T; Sauerbrei W; Bastert G; Ruhland S; Bartik B; Simiantonaki N; Schumacher J; Häcker B; Schumacher M; Schirrmacher V
    J Clin Oncol; 1997 Apr; 15(4):1354-66. PubMed ID: 9193327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients.
    Liebrich W; Schlag P; Manasterski M; Lehner B; Stöhr M; Möller P; Schirrmacher V
    Eur J Cancer; 1991; 27(6):703-10. PubMed ID: 1829908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.
    Harris JE; Ryan L; Hoover HC; Stuart RK; Oken MM; Benson AB; Mansour E; Haller DG; Manola J; Hanna MG
    J Clin Oncol; 2000 Jan; 18(1):148-57. PubMed ID: 10623705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus.
    Bohle W; Schlag P; Liebrich W; Hohenberger P; Manasterski M; Möller P; Schirrmacher V
    Cancer; 1990 Oct; 66(7):1517-23. PubMed ID: 2208003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival.
    Dillman RO; Beutel LD; Barth NM; de Leon C; O'Connor AA; DePriest C; Nayak SK
    Cancer Biother Radiopharm; 2002 Feb; 17(1):51-66. PubMed ID: 11915174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial.
    Schulze T; Kemmner W; Weitz J; Wernecke KD; Schirrmacher V; Schlag PM
    Cancer Immunol Immunother; 2009 Jan; 58(1):61-9. PubMed ID: 18488223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuated veterinary virus vaccine for the treatment of cancer.
    Csatary LK; Eckhardt S; Bukosza I; Czegledi F; Fenyvesi C; Gergely P; Bodey B; Csatary CM
    Cancer Detect Prev; 1993; 17(6):619-27. PubMed ID: 8275514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory.
    Schirrmacher V
    Cancer Immunol Immunother; 2005 Jun; 54(6):587-98. PubMed ID: 15838708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response.
    Zhao L; Mei Y; Sun Q; Guo L; Wu Y; Yu X; Hu B; Liu X; Liu H
    J Immunol; 2014 Jul; 193(2):735-45. PubMed ID: 24943214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
    Hsueh EC; Essner R; Foshag LJ; Ollila DW; Gammon G; O'Day SJ; Boasberg PD; Stern SL; Ye X; Morton DL
    J Clin Oncol; 2002 Dec; 20(23):4549-54. PubMed ID: 12454111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenoviral-expressed recombinant granulocyte monocyte colony-stimulating factor (GM-CSF) enhances protective immunity induced by inactivated Newcastle Disease Virus (NDV) vaccine.
    Wang X; Wang X; Jia Y; Wang C; Han Q; Lu ZH; Yang Z
    Antiviral Res; 2017 Aug; 144():322-329. PubMed ID: 28698014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating viral interference between infectious bronchitis virus and Newcastle disease virus vaccine strains using quantitative reverse transcription-polymerase chain reaction.
    Gelb J; Ladman BS; Licata MJ; Shapiro MH; Campion LR
    Avian Dis; 2007 Dec; 51(4):924-34. PubMed ID: 18251404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor response and 4 year survival-data of patients with advanced renal-cell carcinoma treated with autologous tumor vaccine and subcutaneous R-IL-2 and IFN-alpha(2b).
    Pomer S; Schirrmacher V; Thiele R; Lohrke H; Brkovic D; Staehler G
    Int J Oncol; 1995 May; 6(5):947-54. PubMed ID: 21556623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active specific immunotherapy of renal cell carcinoma: cellular and humoral immune responses.
    Zorn U; Duensing S; Langkopf F; Anastassiou G; Kirchner H; Hadam M; Knüver-Hopf J; Atzpodien J
    Cancer Biother Radiopharm; 1997 Jun; 12(3):157-65. PubMed ID: 10851462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.